Patents Examined by Steven Pohnert
-
Patent number: 11905552Abstract: A digital biosensor for assaying a target nucleic acid and methods of using the biosensor for digitally detecting the target nucleic acid are disclosed wherein the biosensor includes a substrate having a substrate surface and at least two electrodes, a linker molecule having a first moiety conjugated to the substrate surface, a ribonucleoprotein (RNP) conjugated to a second moiety of the linker molecule, and a guide ribonucleic acid (gRNA) having a first sequence capable of binding to the inactive RNP and a second sequence capable of binding to the target nucleic acid.Type: GrantFiled: August 6, 2018Date of Patent: February 20, 2024Assignees: KECK GRADUATE INSTITUTE OF APPLIED LIFE SCIENCES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kiana Aran, Tara deBoer, Irina Conboy
-
Patent number: 11840730Abstract: Aspects of the invention relates to methods and compositions that are useful to reduce bias and increase the reproducibility of multiplex analysis of genetic loci. In some configurations, predetermined preparative steps and/or nucleic acid sequence analysis techniques are used in multiplex analyses for a plurality of genetic loci in a plurality of samples.Type: GrantFiled: November 19, 2020Date of Patent: December 12, 2023Assignee: MOLECULAR LOOP BIOSCIENCES, INC.Inventors: Gregory Porreca, Uri Laserson
-
Patent number: 11834720Abstract: Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, and xx for diagnostic purposes and/or epidemiological typing.Type: GrantFiled: October 10, 2006Date of Patent: December 5, 2023Assignee: GENEOHM SCIENCES, INC.Inventors: Ann Huletsky, Richard Giroux
-
Patent number: 11788141Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD56+ NK cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for mevalonate (diphospho) decarboxylase (MVD), wherein a demethylation or lack of methylation of said gene region is indicative for a CD56+ NK cell, when compared to a non-CD56+ NK cell. The analyses according to the invention can identify CD56+ NK cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying CD56+ NK cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.Type: GrantFiled: September 22, 2016Date of Patent: October 17, 2023Assignee: Precision for Medicine GmbHInventor: Sven Olek
-
Patent number: 11781178Abstract: Provided herein are compositions and methods for the synthesis, amplification, and in vitro transcription of full-length cDNA, or cDNA fragments. Methods are provided for reverse transcription of RNA and amplification for in vitro transcription. Further provided are method for loading of dendritic cells with the RNA and homologous lysate for immune stimulation.Type: GrantFiled: December 17, 2018Date of Patent: October 10, 2023Assignee: Baylor College of MedicineInventors: William K. Decker, Vanaja Konduri
-
Patent number: 11781127Abstract: The present invention provides a method for the isolation of sperm DNA from swabs taken from rape victims without having to perform a change in buffers. Non-sperm cells from the victim are digested with an enzyme and solubilized, and then in the same buffer an enzyme capable of digesting soluble DNA is added and the victim's DNA is degraded, leaving only the rapist's DNA intact. Since no change of buffer is needed, no centrifugation or filtration steps are needed. The inventive method has utility particularly in the forensic science field.Type: GrantFiled: January 11, 2008Date of Patent: October 10, 2023Inventor: Alex Garvin
-
Patent number: 11773458Abstract: Methods for the rapid detection of the presence or absence of BK virus in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting BK virus and kits are provided that are designed for the detection of BK virus.Type: GrantFiled: August 28, 2020Date of Patent: October 3, 2023Assignee: Roche Molecular Systems, Inc.Inventors: Rochak Mehta, Jingtao Sun
-
Patent number: 11761041Abstract: The present invention relates to a method, in particular an in vitro method, for identifying monocytes, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for parkin RBR E3 ubiquitin protein ligase (PARK2), wherein a de-methylation or lack of methylation of said gene region is indicative for a monocyte, when compared to a non-monocyte cell. The analyses according to the invention can identify monocytes on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying monocytes, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Also claimed are kits and specific oligonucleotides for use as primers or probes.Type: GrantFiled: September 22, 2016Date of Patent: September 19, 2023Assignee: Precision for Medicine GmbHInventor: Sven Olek
-
Patent number: 11725243Abstract: The present invention relates to a method, in particular an in vitro method, for identifying follicular helper T cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for leukemia inhibitory factor (LIF), wherein a demethylation of said gene region is indicative for a follicular helper T cell, when compared to a non-follicular helper T cell. The analyses according to the invention can identify follicular helper T cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood cells. The present invention furthermore provides an improved method for quantifying follicular helper T cells in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.Type: GrantFiled: December 4, 2015Date of Patent: August 15, 2023Assignee: Precision for Medicine GmbHInventors: Sven Olek, Ulrich Hoffmüller
-
Patent number: 11697842Abstract: Provided herein are compositions and methods for the synthesis, amplification, and in vitro transcription of full-length cDNA, or cDNA fragments. Methods are provided for reverse transcription of RNA and amplification for in vitro transcription. Further provided are method for loading of dendritic cells with the RNA and homologous lysate for immune stimulation.Type: GrantFiled: December 17, 2018Date of Patent: July 11, 2023Assignee: Baylor College of MedicineInventors: William K. Decker, Vanaja Konduri
-
Patent number: 11680295Abstract: Disclosed are arrays of nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods using SNPs on genes of the bovine interferon tau signaling pathway for improved bovine fertilization rate, or embryo survival, or both.Type: GrantFiled: November 8, 2016Date of Patent: June 20, 2023Assignee: Wisconsin Alumni Research FoundationInventor: Hasan Khatib
-
Patent number: 11643687Abstract: The present invention relates to a method, in particular an in vitro method, for identifying B cells, comprising analyzing the methylation status of at least one CpG position in the mammalian gene region for Low density lipoprotein receptor-related protein 5 (LRP5), wherein a demethylation or lack of methylation of said gene region is indicative for a B cell, when compared to a non-B cell. The analyses according to the invention can identify B cells on an epi-genetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying B cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. Further claimed are kits and specific primers and probes for identifying methylation.Type: GrantFiled: September 22, 2016Date of Patent: May 9, 2023Assignee: Precision for Medicine GmbHInventor: Sven Olek
-
Patent number: 11634747Abstract: A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucleic acids. The treatment of the sample aids in increasing the amount of fetal nucleic acids that can be identified and tested while maintaining the structure and integrity of the fetal nucleic acids.Type: GrantFiled: January 19, 2010Date of Patent: April 25, 2023Assignee: STRECK LLCInventors: M. Rohan Fernando, Kate Chao-Wei Chen
-
Patent number: 11519042Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.Type: GrantFiled: December 20, 2012Date of Patent: December 6, 2022Assignee: BIOMERIEUXInventors: Philippe Perot, François Mallet, Cécile Montgiraud, Nathalie Mugnier
-
Patent number: 11479813Abstract: This application provides methods, kits, probes and primers, that can be used to analyze environmental samples, such as water samples, soil samples, and air samples. The methods and kits can include positive controls, to provide confidence in test results.Type: GrantFiled: October 10, 2017Date of Patent: October 25, 2022Assignee: UVic Industry Partnerships Inc.Inventors: Caren Christiane Helbing, Nicholas Veldhoen
-
Patent number: 11473147Abstract: The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.Type: GrantFiled: December 20, 2012Date of Patent: October 18, 2022Assignee: BIOMERIEUXInventors: Philippe Perot, François Mallet, Nathalie Mugnier
-
Patent number: 11459605Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.Type: GrantFiled: December 18, 2012Date of Patent: October 4, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: François Mallet, Nathalie Mugnier, Philippe Perot
-
Patent number: 11453920Abstract: The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit including at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.Type: GrantFiled: December 19, 2012Date of Patent: September 27, 2022Assignee: BIOMERIEUXInventors: Philippe Perot, François Mallet, Nathalie Mugnier
-
Patent number: 11453916Abstract: The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.Type: GrantFiled: December 17, 2012Date of Patent: September 27, 2022Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYONInventors: François Mallet, Nathalie Mugnier, Philippe Perot
-
Patent number: 11421276Abstract: This invention provides methods and compositions for diagnosing ischemia, ischemia reference expression profiles, and methods for identifying compounds for treating or preventing ischemia.Type: GrantFiled: June 27, 2019Date of Patent: August 23, 2022Assignee: The Regents of the University of CaliforniaInventors: Huichun Xu, Frank R. Sharp